Hansa Biopharma AB (publ) HNSA.ST Stock
Hansa Biopharma AB (publ) Price Chart
Hansa Biopharma AB (publ) HNSA.ST Financial and Trading Overview
| Hansa Biopharma AB (publ) stock price | 30.4 SEK |
| Previous Close | 47.92 SEK |
| Open | 47.92 SEK |
| Bid | 47.88 SEK x 0 |
| Ask | 48.04 SEK x 0 |
| Day's Range | 47.84 - 48.86 SEK |
| 52 Week Range | 41.02 - 105.8 SEK |
| Volume | 28.53K SEK |
| Avg. Volume | 219.28K SEK |
| Market Cap | 2.56B SEK |
| Beta (5Y Monthly) | 0.965134 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -15.83 SEK |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 163.2 SEK |
HNSA.ST Valuation Measures
| Enterprise Value | 2.09B SEK |
| Trailing P/E | N/A |
| Forward P/E | -4.818455 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 17.217005 |
| Price/Book (mrq) | 6.075629 |
| Enterprise Value/Revenue | 14.062 |
| Enterprise Value/EBITDA | -3.362 |
Trading Information
Hansa Biopharma AB (publ) Stock Price History
| Beta (5Y Monthly) | 0.965134 |
| 52-Week Change | -4.82% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 105.8 SEK |
| 52 Week Low | 41.02 SEK |
| 50-Day Moving Average | 50.58 SEK |
| 200-Day Moving Average | 55.03 SEK |
HNSA.ST Share Statistics
| Avg. Volume (3 month) | 219.28K SEK |
| Avg. Daily Volume (10-Days) | 227.84K SEK |
| Shares Outstanding | 52.44M |
| Float | 39.59M |
| Short Ratio | N/A |
| % Held by Insiders | 8.15% |
| % Held by Institutions | 36.63% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -420.0010% |
| Gross Margin | 75.14% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.61% |
| Return on Equity (ttm) | -129.085% |
Income Statement
| Revenue (ttm) | 148.44M SEK |
| Revenue Per Share (ttm) | 3.16 SEK |
| Quarterly Revenue Growth (yoy) | -20.10% |
| Gross Profit (ttm) | 116.05M SEK |
| EBITDA | -620813248 SEK |
| Net Income Avi to Common (ttm) | -678118016 SEK |
| Diluted EPS (ttm) | -14.41 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.29B SEK |
| Total Cash Per Share (mrq) | 24.54 SEK |
| Total Debt (mrq) | 824.41M SEK |
| Total Debt/Equity (mrq) | 198.81 SEK |
| Current Ratio (mrq) | 5.784 |
| Book Value Per Share (mrq) | 7.907 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -579179008 SEK |
| Levered Free Cash Flow (ttm) | -311374368 SEK |
Profile of Hansa Biopharma AB (publ)
| Country | Sweden |
| State | N/A |
| City | Lund |
| Address | ScheelevAegen 22 |
| ZIP | 223 63 |
| Phone | 46 46 16 56 70 |
| Website | https://www.hansabiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 159 |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Q&A For Hansa Biopharma AB (publ) Stock
What is a current HNSA.ST stock price?
Hansa Biopharma AB (publ) HNSA.ST stock price today per share is 30.4 SEK.
How to purchase Hansa Biopharma AB (publ) stock?
You can buy HNSA.ST shares on the Stockholm exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Hansa Biopharma AB (publ)?
The stock symbol or ticker of Hansa Biopharma AB (publ) is HNSA.ST.
Which industry does the Hansa Biopharma AB (publ) company belong to?
The Hansa Biopharma AB (publ) industry is Biotechnology.
How many shares does Hansa Biopharma AB (publ) have in circulation?
The max supply of Hansa Biopharma AB (publ) shares is 52.67M.
What is Hansa Biopharma AB (publ) Price to Earnings Ratio (PE Ratio)?
Hansa Biopharma AB (publ) PE Ratio is now.
What was Hansa Biopharma AB (publ) earnings per share over the trailing 12 months (TTM)?
Hansa Biopharma AB (publ) EPS is -15.83 SEK over the trailing 12 months.
Which sector does the Hansa Biopharma AB (publ) company belong to?
The Hansa Biopharma AB (publ) sector is Healthcare.
Hansa Biopharma AB (publ) HNSA.ST included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| OMX Stockholm All-Share Cap_GI OMXSCAPGI | 456.92 SEK 44.6 USD |
+0.02
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Mid_Cap_ISK_GI OMXNMCISKGI | 622.38 ISK 4.58 USD |
-0.43
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Mid_Cap_DKK_GI OMXNMCDKKGI | 439.38 DKK 64.42 USD |
-0.4
|
— — | — — | — — | — - | — — |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
| OMX Stockholm Health Care PI SX4000PI | 2712.52 SEK 264.78 USD |
<0.01
|
— — | — — | — — | — - | — — |
| NASDAQ OMX Small Cap Sweden GI NOMXSCSEGI | 4086.93 SEK 398.94 USD |
-0.47
|
— — | — — | — — | — - | — — |
| OMX Stockholm Health Care GI SX20GI | 4204.43 SEK 410.4 USD |
-0.07
|
— — | — — | — — | — - | — — |
| OMX Stockholm Pharmaceuticals a SX201030GI | 6954.45 SEK 678.84 USD |
+0.49
|
— — | — — | — — | — - | — — |
| OMX_Stockholm_Mid_Cap_PI OMXSMCPI | 1516.78 SEK 148.06 USD |
-0.02
|
— — | — — | — — | — - | — — |
| OMX Stockholm_GI OMXSGI | 466.5 SEK 45.54 USD |
+0.02
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Mid_Cap_SEK_GI OMXNMCSEKGI | 548.69 SEK 53.56 USD |
+0.07
|
— — | — — | — — | — - | — — |
| OMX_Nordic_Mid_Cap_EUR_GI OMXNMCEURGI | 439.19 EUR 480.1 USD |
-0.42
|
— — | — — | — — | — - | — — |
| OMX Affarsvarldens Generalindex OMXAFGX | 923.83 SEK 90.18 USD |
-0.03
|
— — | — — | — — | — - | — — |
| NASDAQ OMX Small Cap Sweden PI NOMXSCSEPI | 2564.43 SEK 250.32 USD |
-0.59
|
— — | — — | — — | — - | — — |
| OMX Stockholm Health Care PI SX20PI | 3276.93 SEK 319.87 USD |
-0.07
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}